Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Hydrochlorothiazide; Telmisartan

Criteria

Inclusion Criteria:

• Hypertensive patients seen by the physician requiring antihypertensive treatment

Exclusion Criteria:

• According to the local drug information